Skip to main content

Prostate and Urologic Cancers

Conducts and supports research on the prevention and early detection of prostate and bladder cancers. Develops and supports prevention trials and evaluation of new agents, surrogate biomarkers, and emerging technologies for identifying premalignant lesions.

On This Page

All Heading 2s will automatically be pulled in to this list.
Do not edit the content on this template.

Major Programs

Staff List

Grid View

Photo	Name, Email, Phone	Room	Group(s)/Office
	Asefa, Mela mela.asefa@nih.gov 240-276-6422	5E328	Program Support Assistant \| Breast and Gynecologic Cancer Program Support Assistant \| Prostate and Urologic Cancer
	House, Margaret, RN, B.S.N. margaret.house@nih.gov 240-276-7047	5E306	Deputy Chief \| Prostate and Urologic Cancer
	Parnes, Howard L., M.D. howard.parnes@nih.gov 240-276-7045	5E302	Chief \| Prostate and Urologic Cancer

Grants

PI Name Sort descending	PI Organization	Title	Grant Number	Program Official
Elmore, Joann G	University Of California Los Angeles United States	Optimizing the Human-Computer Interaction in Pathology: Understanding the Impact of Computer-Aided Diagnosis Tools on Pathologists' Interpretive Performance	1R01CA288824-01A1	Claire Zhu, Ph.D.
Elswick, Ronald K	Virginia Commonwealth University United States	A Randomized Controlled Trial using a Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults with Cancer	5R01CA286799-03	Asad Umar, D.V.M., Ph.D.
Esserman, Laura J	University Of California, San Francisco United States	Extending the Diversity, Reach, and Generalizability of the WISDOM Study	5R01CA237533-05	Claire Zhu, Ph.D.
Esserman, Laura J	University Of California, San Francisco United States	WISDOM: A platform to optimize subtype-specific screening and prevention	5P01CA281826-02	Brandy Heckman-Stoddard, Ph.D., M.P.H.
Fabian, Carol J.	University Of Kansas Medical Center United States	Biomarker-Based Phase IIB Trial of (Bazedoxifene-Conjugated Estrogen) to Reduce Risk for Breast Cancer	5R01CA249437-05	Edward Sauter, M.D., Ph.D.
Fahrmann, Johannes F	University Of Tx Md Anderson Can Ctr United States	Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer	5U01CA282216-03	Claire Zhu, Ph.D.
Faller, Bryan	Decatur Memorial Hospital United States	Heartland Cancer Research NCORP	3UG1CA189830-11S1	Vanessa A. White, M.P.H.
Farrar, Christian T	Massachusetts General Hospital United States	Novel metabolomic contrast probes for human lung cancer characterization	4R01CA273010-04	Guillermo Marquez, Ph.D.
Feng, Ziding	Fred Hutchinson Cancer Center United States	Consortium on Translational Research in Early Detection of Liver Cancer:Data Management and Coordinating Center (DMCC)	5U24CA230144-09	Guillermo Marquez, Ph.D.
Fiol, Guilherme Del	University Of Utah United States	GARDE: Scalable Clinical Decision Support for Individualized Cancer Risk Management	5U24CA274582-03	Christos Patriotis, Ph.D., M.Sc.
Fitzgibbon, Marian L.	University Of Illinois At Chicago United States	Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer Risk	5R01CA250390-05	Young Kim, Ph.D.
Flory, James H	Sloan-Kettering Inst Can Research United States	Managing metabolic disruption in pancreatic cancer to prevent weight loss and improve quality of life	5R21CA277464-02	Gabriela Riscuta, M.D., CNS
Flowers, Lisa C.	Emory University United States	Screening Strategies Among High-Risk Populations for Anal Cancer	5R01CA285198-03	Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Flowers, Lisa C.	Emory University United States	Georgia Consortium to Eliminate Cervical Cancer in Women Living with HIV (GaCECC-WLWH)	5UG1CA284884-03	Maria Silvina Frech, Ph.D., M.S.
Flynn, Kathryn E	Medical College Of Wisconsin United States	Symptom Monitoring using Patient-Reported Outcomes to Optimize Medication Use (SyMPTOM)	5R01CA285925-02	Brandy Heckman-Stoddard, Ph.D., M.P.H.